Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the completion of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting worldwide rights to its nose-to-brain (N2B) delivery system intellectual property within the fields of biodefense and Alzheimer’s disease. In exchange, Oncotelic received $12.5 million in Series B convertible preferred stock. The agreement establishes a new initiative focused on central nervous system (CNS)-targeted therapeutics, while supporting Oncotelic’s strategy to monetize its portfolio and retain control of core assets.
The N2B platform enables intranasal delivery directly to the CNS, bypassing the blood-brain barrier to facilitate rapid therapeutic action and targeted neurological engagement. This technology has applications in biodefense medical countermeasures and neurodegenerative conditions, making it a valuable asset for addressing urgent medical needs. Under the agreement, Lunai Bioworks will develop the platform within the specified fields, while Oncotelic retains rights for other indications, including Parkinson’s disease and sexual dysfunction, leveraging its internal expertise in CNS therapeutics and biodefense.
This transaction is significant because it allows Oncotelic to unlock value from its portfolio without relinquishing control over its broader pipeline. The company, a clinical-stage biopharmaceutical firm focused on oncology and immunotherapy products, benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
The implications for the industry are notable. The N2B delivery system could potentially revolutionize treatment for Alzheimer’s disease and biodefense threats by providing a non-invasive route to the brain. For Oncotelic, the $12.5 million infusion in preferred stock strengthens its financial position while allowing it to focus on its core oncology and rare disease programs. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
This deal also highlights the growing interest in CNS drug delivery technologies, particularly those that can bypass the blood-brain barrier. As the population ages, the demand for effective Alzheimer’s treatments is expected to rise, and biodefense applications remain a priority for national security. By partnering with Lunai Bioworks, Oncotelic is positioning itself to capitalize on these trends while maintaining flexibility for future developments.
For more information, visit the full press release at https://ibn.fm/IWUpe and the company’s newsroom at https://ibn.fm/OTLC.
